mTOR, S6 and AKT expression in relation to proliferation and apoptosis/autophagy in glioma

Anticancer Research

Volumn 29, Issue 8, 2009, Pages 3087-3094

  Annovazzi, Laura ^a   Mellai, Marta ^a   Caldera, Valentina ^a   Valente, Guido ^b   Tessitore, Luciana ^c   Schiffer, Davide ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b Clinical and Experimental Medical Department   (Italy)

^c UNIVERSITY OF EASTERN PIEDMONT   (Italy)

Author keywords

Apoptosis; Gliomas; mTOR; Proliferation; S6

Indexed keywords

BECLIN 1; CASPASE 3; EPIDERMAL GROWTH FACTOR RECEPTOR; KI 67 ANTIGEN; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MONOCLONAL ANTIBODY KI 67; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; S6 KINASE;

APOPTOSIS; ARTICLE; AUTOPHAGY; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; GLIOBLASTOMA; GLIOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LABELING INDEX; MOLECULAR BIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS REGULATION; WESTERN BLOTTING;

APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; AUTOPHAGY; BLOTTING, WESTERN; CASPASE 3; CELL PROLIFERATION; GLIOMA; HUMANS; IMMUNOENZYME TECHNIQUES; KI-67 ANTIGEN; MEMBRANE PROTEINS; PHOSPHORYLATION; POLY(ADP-RIBOSE) POLYMERASES; PROTEIN KINASES; PROTO-ONCOGENE PROTEINS C-AKT; RIBOSOMAL PROTEIN S6 KINASES; UBIQUITIN-PROTEIN LIGASES;

EID: 68549136609     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Richardson CJ, Bröenstrup M, Fingar DC, Jülich K, Ballif BA, Gygi S and Blenis J: SKAR is a specific target of S6 kinase 1 in cell growth control. Curr Biol 14: 1540-1549, 2004. (Pubitemid 39290051)
2. Lawrence JC Jr and Brunn GJ: Insulin signaling and the control of PHAS-I phosphorylation. Prog Mol Subcell Biol 26: 1-31, 2001.
3. Inoki K, Li Y, Zhu T, Wu J and Guan KL: TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat Cell Biol 4: 648-657, 2002. (Pubitemid 34993700)
4. Manning BD, Tee AR, Logsdon MN, Blenis J and Cantley LC: Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway. Mol Cell 10: 151-162, 2002. (Pubitemid 34876569)
5. Gingras AC, Raught B and Sonenberg N: Regulation of translation initiation by FRAP/mTOR. Genes Dev 15: 807-826, 2001.
6. Dhavan R and Tsai LH: A decade of CDK5. Nat Rev Mol Cell Biol 2: 749-759, 2001.
7. Lim AC, Qu D and Qi RZ: Protein-protein interactions in Cdk5 regulation and function. Neurosignals 12: 230-238, 2003. (Pubitemid 37548238)
8. Hou Z, He L and Qi RZ: Regulation of S6 kinase 1 activation by phosphorylation at ser-411. J Biol Chem 282: 6922-6928, 2007. (Pubitemid 47093644)
9. Volarević S and Thomas G: Role of S6 phosphorylation and S6 kinase in cell growth. Prog Nucleic Acid Res Mol Biol 65: 101-127, 2001.
10. Jaeschke A, Hartkamp J, Saitoh M, Roworth W, Nobukuni T, Hodges A, Sampson J, Thomas G and Lamb R: Tuberous sclerosis complex tumor suppressor-mediated S6 kinase inhibition by phosphatidylinositide-3-OH kinase is mTOR independent. J Cell Biol 159: 217-224, 2002. (Pubitemid 35283391)
11. Holz MK and Blenis J: Identification of S6 kinase 1 as a novel mammalian target of rapamycin (mTOR)-phosphorylating kinase. J Biol Chem 280: 26089-26093, 2005. (Pubitemid 41022201)
12. Yokogami K, Wakisaka S, Avruch J and Reeves SA: Serine phosphorylation and maximal activation of STAT3 during CNTF signaling is mediated by the rapamycin target mTOR. Curr Biol 10: 47-50, 2000. (Pubitemid 30057415)
13. Riemenschneider MJ, Betensky RA, Pasedaq SM and Louis DN: AKT activation in human glioblastomas enhances proliferation via TSC2 and S6 kinase signaling. Cancer Res 66: 5618-5623, 2006.
14. Rao RD, Mladek AC, Lamont JD, Goble JM, Erlichman C, James CD and Sarkaria JN: Disruption of parallel and converging signaling pathways contributes to the synergistic antitumor effects of simultaneous mTOR and EGFR inhibition in GBM cells. Neoplasia 7: 921-929, 2005.
15. Hosoi H, Dilling MB, Shikata T, Liu LN, Shu L, Ashmun RA, Germain GS, Abraham RT and Houghton PJ: Rapamycin causes poorly reversible inhibition of mTOR and induces p53-independent apoptosis in human rhabdomyosarcoma cells. Cancer Res 59: 886-894, 1999. (Pubitemid 29086744)
16. Harada H, Andersen JS, Mann M, Terada N and Korsmeyer SJ: p70S6 kinase signals cell survival as well as growth, inactivating the pro-apoptotic molecule BAD. Proc Natl Acad Sci USA 98: 9666-9670, 2001. (Pubitemid 32769360)
17. Castedo M, Ferri KF and Kroemer G: Mammalian target of rapamycin (mTOR): pro- and anti-apoptotic. Cell Death Differ 9: 99-100, 2002. (Pubitemid 34144768)
18. Desai BN, Myers BR and Schreiber SL: FKBP12-rapamycin-associated protein associates with mitochondria and senses osmotic stress via mitochondrial dysfunction. Proc Natl Acad Sci USA 99: 4319-4324, 2002.
19. Shacka JJ, Roth KA and Zhang J: The autophagy-lysosomal degradation pathway: role in neurodegenerative disease and therapy. Front Biosci 13: 718-736, 2008.
20. Kondo Y, Kanzawa T, Sawaya R and Kondo S: The role of autophagy in cancer development and response to therapy. Nat Rev Cancer 5: 726-734, 2005. (Pubitemid 41486365)
21. Rubinsztein DC, Gestwicki JE, Murphy LO and Klionsky DJ: Potential therapeutic applications of autophagy. Nat Rev Drug Discov 6: 304-312, 2007.
22. Fujiwara K, Iwado E, Mills GB, Sawaya R, Kondo S and Kondo Y: Akt inhibitor shows anticancer and radiosensitizing effects in malignant glioma cells by inducing autophagy. Int J Oncol 31: 753-760, 2007.
23. Yokoyama T and Kondo S: Roles of mTOR and STAT3 in autophagy induced by telomere 3′ overhang-specific DNA oligonucleotides. Autophagy 3: 496-498, 2007. (Pubitemid 47293738)
24. Aoki H, Takada Y, Kondo S, Sawaya R, Aggarwal BB and Kondo Y: Evidence that curcumin suppresses the growth of malignant gliomas in vitro and in vivo through induction of autophagy: role of Akt and extracellular signal-regulated kinase signaling pathways. Mol Pharmacol 72: 29-39, 2007. (Pubitemid 46998522)
25. Weppler SA, Krause M, Zyromska A, Lambin P, Baumann M and Wouters BG: Response of U87 glioma xenografts treated with concurrent rapamycin and fractionated radiotherapy: possible role for thrombosis. Radiother Oncol 82: 96-104, 2007. (Pubitemid 46097131)
26. Mounier N, Vignot S and Spano JP: Update on clinical activity of CCI779 (temsirolimus), mTOR inhibitor. Bull Cancer 93: 1139-1143, 2006. (Pubitemid 46032379)
27. Panner A, Parsa AT and Pieper RO: Use of APO2L/TRAIL with mTOR inhibitors in the treatment of glioblastoma multiforme. Expert Rev Anticancer Ther 6: 1313-1322, 2006. (Pubitemid 44575582)
28. Fan QW, Knight ZA, Goldenberg DD, Yu W, Mostov KE, Stokoe D, Shokat KM and Weiss WA: A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma. Cancer Cell 9: 327-328, 2006. (Pubitemid 43668732)
29. Kaper F, Dornhoefer N and Giaccia AJ: Mutations in the PI3K/PTEN/TSC2 pathway contribute to mammalian target of rapamycin activity and increased translation under hypoxic conditions. Cancer Res 66: 1561-1569, 2006. (Pubitemid 43259938)
30. Homburg S, Visochek L, Moran N, Dantzer F, Priel E, Asculai E, Schwartz D, Rotter V, Dekel N and Cohen-Armon M: A fast signal-induced activation of Poly(ADP-ribose) polymerase: a novel downstream target of phospholipase c. J Cell Biol 150: 293-307, 2000. (Pubitemid 30491354)
31. Ullrich O, Diestel A, Eyüpoglu IY and Nitsch R: Regulation of microglial expression of integrins by poly(ADP-ribose) polymerase-1. Nat Cell Biol 3: 1035-1042, 2001. (Pubitemid 33130453)
32. Caldera V, Mellai M, Annovazzi L, Valente G, Tessitore L and Schiffer D: STAT3 expression and its correlation with proliferation and apoptosis/autophagy in gliomas. J Oncology, 2008.
33. Wang H, Wang H, Zhang W, Huang HJ, Liao WS and Fuller GN: Analysis of the activation status of Akt, NFkappaB and Stat3 in human diffuse gliomas. Lab Invest 84: 941-951, 2004.
34. Mizoguchi M, Betensky R, Batchelor T, Bernay DC, Louis DN and Nutt CL: Activation of STA3, MAPK, and AKT in malignant astrocytic gliomas: correlation with EGFR status, tumor grade, and survival. J Neuropathol Exp Neurol 65: 1181-1188, 2006. (Pubitemid 44885942)
35. Rosner M, Hanneder M, Freilinger A and Hengstschläger M: Nuclear/cytoplasmic localization of Akt activity in the cell cycle. Amino Acids 32: 341-345, 2007. (Pubitemid 46559590)
36. Iwamaru A, Szymanski S, Iwado E, Aoki H, Yokoyama T, Fokt I, Hess K, Conrad C, Madden T, Sawaya R, Kondo S, Priebe W and Kondo Y: A novel inhibitor of the STAT3 pathway induces apoptosis in malignant glioma cells both in vitro and in vivo. Oncogene 26: 2435-2444, 2007. (Pubitemid 46597261)
37. Schiffer D: Brain Tumor Pathology: Hot Spots and Pitfalls in the Current Histological Diagnosis. Dordrecht, Springer, pp. 272, 2006.
38. Rahaman SO, Harbor PC, Chernova O, Barnett GH, Vogelbaum MA and Haque SJ: Inhibition of constitutively active Stat3 suppresses proliferation and induces apoptosis in glioblastoma multiforme cells. Oncogene 21: 8404-8413, 2002. (Pubitemid 36054883)
39. Mellai M and Schiffer D: Apoptosis in brain tumors: prognostic and therapeutic considerations. Anticancer Res 27: 437-448, 2007. (Pubitemid 46370590)
40. Gross A, Yin XM, Wang K, Wei MC, Jockel J, Milliman C, Erdjument-Bromage H, Tempst P and Korsmeyer SJ: Caspase cleaved BID targets mitochondria and is required for cytochrome c release, while BCL-XL prevents this release but not tumor necrosis factor-R1/Fas death. J Biol Chem 274: 1156-1163, 1999. (Pubitemid 129535271)
41. Ashley DM, Riffkin CD, Muscat AM, Knight MJ, Kaye AH, Novak U and Hawkins CJ: Caspase 8 is absent or low in many ex vivo gliomas. Cancer 104: 1487-1496, 2005. (Pubitemid 41356164)
42. Alva AS, Gultekin SH and Baehrecke EH: Autophagy in human tumors: cell survival or death? Cell Death Differ 11: 1046-1048, 2004.
43. Tessitore L: Understanding autophagy in cell death control. Curr Pharm Design, 2008.
44. Miracco C, Cosci E, Oliveri G, Luzi P, Pacenti L, Monciatti I, Mannucci S, De Nisi MC, Toscano M, Malagnino V, Falzarano SM, Pirtoli L and Tosi P: Protein and mRNA expression of autophagy gene beclin 1 in human brain tumours. Int J Oncol 30: 429-436, 2007.
45. Takeuchi H, Kondo Y, Fujiwara K, Kanzawa T, Aoki H, Mills GB and Kondo S: Synergistic augmentation of rapamycin-induced autophagy in malignant glioma cells by phosphatidylinositol 3-kinase/protein kinase B inhibitors. Cancer Res 65: 3336-3346, 2005. (Pubitemid 40524618)
46. Yao KC, Komata T, Kondo Y, Kanzawa T, Kondo S and Germano IM: Molecular response of human glioblastoma multiforme cells to ionizing radiation: cell cycle arrest, modulation of the expression of cyclin-dependent kinase inhibitors and autophagy. J Neurosurg 98: 378-384, 2003. (Pubitemid 36151035)
47. Daido S, Yamamoto A, Fujiwara K, Sawaya R, Kondo S and Kondo Y: Inhibition of the DNA-dependent protein kinase catalytic subunit radiosensitizes malignant glioma cells by inducing autophagy. Cancer Res 65: 4368-4375, 2005. (Pubitemid 40775676)
48. Ito H, Daido S, Kanzawa T, Kondo S and Kondo Y: Radiation-induced autophagy is associated with LC3 and its inhibition sensitizes malignant glioma cells. Int J Oncol 26: 1401-1410, 2005.